This is important from both safety and effectiveness perspectives, since a portion of patients may experience ADRs or drug administration barriers (e.g., scoliosis/spinal fusion) and may thus demand a new DMD with a peroral (risdiplam) or intravenous (onasemnogene abeparvovec) route of administration. Here, DMD is linked to scoliosis.